Slow-wave Enhancement in Adults Aged 30-49

January 25, 2021 updated by: University of Wisconsin, Madison

Optimizing Peripheral Sensory Stimulation to Induce Sleep Slow Waves

A single-site, randomized study to assess the effectiveness of different types of closed-loop auditory stimulation on slow-wave enhancement using SmartSleep in an astronaut-like sample of adults between the ages of 30 and 55. Secondary analyses will be performed to determine whether slow-wave enhancement influences neurobehavioral performance in this population. Participants will be on study for 8 weeks.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The investigators seek to determine the extent to which various closed-loop auditory stimulation protocols (continuous fixed interval, block, in-phase adjustable) differentially affect slow-wave sleep. Participants will run the study for eight weeks, which includes wearing the SmartSleep device nightly, and completing one 3-min and one 20-min cognitive assessment battery each day, as well as computerized post-sleep questionnaires each morning, sleepiness scales three times a day, and a weekly evaluation of device comfort. This study will employ various types of auditory stimulation in order to determine 1) which stimulation pattern is maximally effective at enhancing slow wave activity (SWA) and 2) to assess cognitive performance associated with each stimulation algorithm. The study requires a longer duration so that sufficient data on each distinct type of stimulation may be collected.

Participants will be instructed to wear the SmartSleep device at home for three two-week periods, and will complete 10 nights per period of continuous fixed interval, block, or in-phase adjustable stimulation (in randomized order). Between each of these periods, participants will complete one week of sham condition (this condition records sleep EEG without any stimulation and is used to define each participant's typical sleep). During all eight weeks, participants will complete a 20-minute cognitive assessment in the evening, a five-minute cognitive assessment in the morning, and respond to the Karolinska Sleepiness Scale three times per day. The cognitive assessments will be accompanied by short questionnaires. Participants will receive text message reminders from study staff when it is time to perform these assessments.

Primary objective: Determine which stimulation type (e.g., Block stimulation, Fixed ITI, in-phase) is most effective at enhancing slow-waves slow-wave sleep relative to baseline sleep in a group of astronaut-like subjects in an ecologically valid setting.

Main secondary objective: Determine the extent to which various closed-loop auditory stimulation protocols (continuous fixed interval, block, inphase adjustable) differentially affect various aspects of neurobehavioral function using a set validated cognitive tasks as part of the Cognition battery.

Other secondary objectives: Explore the relationships between improvements in SWA and measures of subjective sleepiness as assessed by the Karolinska Sleepiness Scale

Study Type

Interventional

Enrollment (Actual)

28

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Wisconsin
      • Madison, Wisconsin, United States, 53719
        • University of Wisconsin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 49 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Able to provide written informed consent
  • Able to understand and speak English
  • Left or right-handed participants may be included
  • Participants have access to a cell phone that can receive text message reminders from study staff
  • Participants have self-reported sleep latency (time taken to fall asleep) > 30 minutes no more than once per week
  • Participants have self-reported wake time after sleep onset ≤ 30 minutes
  • Participants with Body Mass Index (BMI) < 35 kg/m2 AND
  • Participants self-report using an alarm to wake up ≥ 5 days a week
  • Participants self-report sleeping one or more hours longer on weekends (or when given the opportunity) than they do on a typical work night

Exclusion Criteria:

  • Participants who self-report taking medications that could affect sleep patterns
  • Participants who have had travel in the last 2 weeks or who intend to travel during the experimental weeks with time zone shifts >3h
  • Participants unlikely to comply with the protocol (e.g., uncooperative attitude)
  • Individuals who self-report a current severe or chronic medical condition or sleep disorder that may affect sleep patterns
  • Individuals who self-report a history of recurrent seizures or epilepsy or family history of hereditary epilepsy or have a history of medical conditions that could increase the chance of seizures (e.g. stroke, aneurysm, brain surgery, structural brain lesion)
  • Participants who report not being consistent in their daily use of alcohol, caffeine, or nicotine
  • Participants who are pregnant
  • Participants who are night shift workers
  • Individuals who self-report severe contact dermatitis or allergy to silicone, nickel or silver
  • Individuals who self-report moderate hearing loss
  • Self-reported history of excessive alcohol intake- selfreport > 21 drinks / wk or binge alcohol consumption ( >5 drinks per day)
  • Excessive caffeine consumption (> 7 cups) combining all caffeinated drinks regularly absorbed during workdays. Caffeine intake must be regular and maintained throughout study and on testing days
  • Participants who do not have internet access at home
  • Participants who express unwillingness to forego napping on weekdays during the study
  • Participants who smoke
  • Participants with high risk of Obstructive Sleep Apnea (OSA) based on STOP-BANG Questionnaire ("yes" on at least 4 of 8 questions)
  • High Risk of Restless Legs Syndrome (RLS) based on the short form Cambridge-Hopkins Screening questionnaire
  • High Risk of Insomnia based on Insomnia Severity Index (score of 22 or higher)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Philips SmartSleep Device

Participants will be instructed to sleep wearing the SmartSleep device at home for eight weeks, which will include three (3) two-week periods, one each of the following (in randomized order):

  • continuous fixed interval (ITI): SmartSleep will provide 1 Hz, inter-tone interval stimulation continuous during deep sleep opportunities
  • block: SmartSleep will provide 5s ON versus 5s OFF,1Hz inter-tone interval stimulation
  • in-phase adjustable: SmartSleep will provide constant stimulation with tones timed to be delivered during each upstate of the slow wave

Between periods 1 and 2 and between periods 2 and 3, subjects will undergo one week of sham condition during which SmartSleep will record EEG during sleep using a no-volume sham stimulation

closed-loop auditory stimulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Slow Wave Activity between Audio Stimulation Condition and Sham Condition
Time Frame: up to 8 weeks
To compare the three different types of stimulation, a common outcome was selected which is the change in slowwave activity between periods where the stimulation is applied versus equivalent periods, in a sham condition, where the stimulation is not applied but would have been applied. Three different conditions defined in the arm description will be measured: continuous fixed interval, block, and in-phase adjustable; each compared to the sham condition. Participant is blinded to each condition; all data collected over 8 weeks.
up to 8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Global Cognition Battery Score per Stimulation Condition
Time Frame: up to 8 weeks
Cognition is a brief electronic battery that assesses several domains of cognitive function including attention, executive function, reaction time, short-term memory, working memory, spatial ability, and risk taking. Performance will be assessed under each stimulation condition and sham to determine whether enhancement impacts global performance. Total range of possible scores 10-100 where higher scores indicate increased cognition.
up to 8 weeks
Karolinska Sleepiness Scale Score
Time Frame: up to 8 weeks
These scales will be analyzed for changes in subjective sleepiness and perceived sleep quality between periods of different types of auditory stimulation and sham condition. Participants will be assessed 3 times daily (morning, afternoon, and evening), they will rate their alertness on a scale of 1 (extremely alert) to 9 (extremely sleepy, fighting sleep).
up to 8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Giulio Tononi, MD, PhD, University of Wisconsin, Madison

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 16, 2019

Primary Completion (Actual)

December 4, 2020

Study Completion (Actual)

December 4, 2020

Study Registration Dates

First Submitted

October 26, 2020

First Submitted That Met QC Criteria

October 30, 2020

First Posted (Actual)

November 2, 2020

Study Record Updates

Last Update Posted (Actual)

January 28, 2021

Last Update Submitted That Met QC Criteria

January 25, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • 2015-0337 Sub-Study 2
  • A538900 (Other Identifier: UW Madison)
  • SMPH\PSYCHIATRY\PSYCHIATRY (Other Identifier: UW Madison)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sleep

Clinical Trials on Philips SmartSleep

Subscribe